---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-099969"
form_type: "8-K"
ticker: "HOTH"
cik: "0001711786"
company_name: "Hoth Therapeutics, Inc."
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:24:41.688215+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Hoth Therapeutics updates corporate presentation with clinical milestones and cash position

## Summary
- HT-001 Phase 2a open-label cohort showed promising results; case study published Sept 2024.
- HT-KIT IND-enabling tox studies initiated Q1 2024; target IND submission Q4 2026.
- HT-ALZ patent awarded Q3 2024; preclinical studies at Washington University completed.
- HT-VA license from Veteran's Affairs obtained Q1 2025; CRADA executed Q2 2025.
- 15.4M shares outstanding as of Oct 14, 2025; cash sufficient for clinical and preclinical programs.

## SEC filing metadata
- accession: 0001213900-25-099969
- form_type: 8-K
- ticker: HOTH
- cik: 0001711786
- company_name: Hoth Therapeutics, Inc.
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000121390025099969/0001213900-25-099969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000121390025099969/ea0261354-8k_hoth.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-099969
- JSON: https://secwatch.observer/filing/0001213900-25-099969.json
- Plain text: https://secwatch.observer/filing/0001213900-25-099969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.